Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2015) 39 EP77 | DOI: 10.1530/endoabs.39.EP77

BSPED2015 e-Posters Late effects of cancer treatment (2 abstracts)

Impact of haematopoietic stem cell transplantation with total body irradiation on apparent bone mineral density in childhood leukaemia survivors

Christina Wei 1 , Ruth Elson 1 , Rachel Cox 1 , Karin Bradley 2 , Michael Stevens 1 & Elizabeth Crowne 1


1Bristol Royal Hospital for Children, Bristol, UK; 2Bristol Royal Infirmary, Bristol, UK.


Background: Reduced bone mineral density (BMD) z-scores from Dual energy X-Ray absorptiometry (DEXA) have been reported in childhood HSCT survivors. However, BMD z-scores are unreliable in patients with short stature.

Objective: To investigate the influence of HSCT/TBI on size-corrected BMD in childhood leukaemia survivors.

Method: Post-pubertal leukaemia survivors (16–26 years) treated with HSCT/TBI (10–14.4 Gy) (n=21, ten male) at mean aged 9.3 (1.0–10.8) years were compared with patients treated with chemotherapy-only (n=28, 11 male). All had had endocrine evaluations and were on replacement hormones where appropriate. No patients were on long-term steroid therapy. Assessments: anthropometry (height, weight), DEXA scanning (Lunar Prodigy fan beam) [BMD-z-scores, bone mineral content (BMC), bone area (BA)] and vitamin D levels. Size-corrected BMD [i.e. Bone Mineral Apparent Density (BMAD)] were represented as total-BMAD (BMADT)=BMC/total body BA^2/height and Lumbar spine-BMAD (BMADL2-4)=BMDL2-4×[4/(π×width)]. Analysis: student’s t-tests and Pearson’s correlations (5% significance).

Results: HSCT/TBI compared with chemotherapy-only survivors had lower total BMD z-scores (−0.74 vs 0.19, P=0.012), but were lighter (P<0.001) and shorter (P<0.001). Total-BMD correlated positively with height-SDS, weight-SDS, fat and lean masses (all P<0.001). Size corrected BMD showed no mean(SD) differences between HSCT and chemotherapy-only patients: BMADT (0.089 (0.008) vs 0.086 (0.007), P=0.13); BMADL2-4 (0.38 (0.057) vs 0.37 (0.056), P=0.33). There were no relationships between BMADT or BMADL2–4 with age at or time from primary diagnosis in both groups; or with age at and time from HSCT/TBI in HSCT/TBI group. HSCT/TBI survivors showed no relationships between BMADT or BMADL2–4 with serum Vitamin D (P=0.13, P=0.21) or presence of endocrine disorders (growth hormone deficiency (P=0.16, P=0.46), hypothyroidism (P=0.53, P=0.58), gonadal failure (P=0.33, P=0.43)).

Conclusions: BMD must be corrected for size for appropriate interpretation to avoid over-diagnosis of osteopenia. Oncology treatment effects on long-term peak bone mass need further evaluation.

Volume 39

43rd Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.